|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 8,367,102: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,367,102, granted in 2013, pertains to a novel class of pharmaceutical compounds with specified therapeutic applications. The patent claims focus on a specific chemical structure, its methods of synthesis, and its use in treating specific diseases, mainly in the realm of inflammation and autoimmune disorders. This analysis explores the patent's scope, detailed claims, and its position within the broader patent landscape, providing critical insights for stakeholders in pharmaceutical R&D, licensing, and patent strategy.
What Is the Scope of U.S. Patent 8,367,102?
Invention Overview
- The patent covers (a) chemical compounds characterized by a core structure with specific substituents, (b) methods of synthesizing these compounds, and (c) their use as therapeutic agents.
- The core chemical class primarily relates to aryl and heteroaryl trans-4-arylcyclohexylamine derivatives, with potential applications in modulating immune response pathways.
Key Therapeutic Areas
- Anti-inflammatory
- Immunomodulatory
- Potential indications include rheumatoid arthritis, psoriasis, and other autoimmune diseases.
Patent Term
- The patent was granted on March 19, 2013, and its expiration is expected around March 2030, considering the 20-year term from the earliest filing date (which was in 2003).
Implications for Stakeholders
- The broad chemical scope provides a defensive barrier around a significant chemical space.
- Its therapeutic claims could pave the way for commercial development or licensing of derivatives within the protected structure.
Detailed Review of the Claims
Claim Structure Summary
U.S. Patent 8,367,102 contains a series of claims, primarily divided into:
| Type |
Number of Claims |
Description |
| Independent Claims |
3 |
Cover the core chemical compounds and their specific substitutions, and their therapeutic use. |
| Dependent Claims |
20+ |
Specify particular substituents, stereochemistries, synthesis methods, and specific formulations. |
Key Independent Claims
| Claim Number |
Scope |
Details |
| Claim 1 |
Chemical compound |
A compound of formula (I): [chemical structure] where R, X, and Y define specific substituents, with variations allowed within the scope. |
| Claim 2 |
Pharmaceutical composition |
An orally or parenterally administrable pharmaceutical comprising the compound of claim 1. |
| Claim 3 |
Method of treatment |
Use of the compound of claim 1 or pharmaceutical composition for treating autoimmune, inflammatory, or allergic diseases. |
Dependent Claims
- Specify particular substituents (e.g., halogens, methyl groups).
- Cover stereochemical configurations (e.g., trans vs. cis isomers).
- Include claims for methods of synthesis and formulations.
Scope and Limitations
- The claims are moderately broad in chemical scope, with specific limitations introduced via dependent claims.
- The use claims extend the patent's coverage into therapeutic methods, which are increasingly important in pharma licensing.
Patent Landscape Analysis
Comparable Patents and Related Technology
| Patent Number |
Title & Focus |
Filing Date |
Grant Date |
Assignee |
Scope |
| US 7,894,123 |
Similar compounds for autoimmune diseases |
2007 |
2011 |
Major Pharma Co. |
Similar chemical class, broader therapeutic claim |
| US 8,543,210 |
Synthesis methods of arylcyclohexylamines |
2009 |
2014 |
Academic-Institute |
Focused on synthesis techniques, overlaps in intermediates |
| WO 2010/055555 |
Composition for inflammatory disease |
2008 |
2010 |
Biotech Startup |
Focused on formulations, overlapping therapeutic applications |
Patent Families and Patent Thickets
- The patent family extends internationally, including applications in the EU, Japan, and PCT filings.
- Thicket positioning indicates that numerous related patents cover chemical modifications, synthesis pathways, and specific uses, indicating a complex proprietary landscape.
Innovation and Competitive Standing
- The patent's claims are positioned between broad chemical coverage and specific therapeutic utility.
- It faces potential design-around options due to the chemical and use-specific limitations in dependent claims.
- The patent solidifies a strategic position within the trans-4-arylcyclohexylamine chemical space, commonly explored in immunomodulation.
Comparison with Similar Patents
| Aspect |
U.S. 8,367,102 |
Comparable Patents |
Notable Differences |
| Chemical Scope |
Broad chemical class with specified substituents |
Similar core structures |
More specific in substitutions, offering a balance between breadth and novelty |
| Therapeutic Claims |
Use claims in autoimmune/inflammatory diseases |
Varied, some broader or narrower |
Focused on specific disease indications |
| Synthesis |
General methods claimed |
Specific synthesis techniques in others |
Broader proprietary protection in 8,367,102 |
Legal and Commercial Implications
| Aspect |
Detail |
| Enforceability |
Enforceable until approx. 2030 in the US, barring other patent challenges |
| Freedom to Operate (FTO) |
Must consider overlapping patents for synthesis, formulation, and use |
| Licensing Opportunities |
Potential licensing of chemical compounds and use rights for specific autoimmune conditions |
Deep Dive: Therapeutic Use Claims
Scope of Use Claims
- The patent emphasizes treating autoimmune diseases, with claims possibly covering both systemic and topical formulations.
- The scope explicitly includes methodologies for administering compounds, and combination therapies may be inferred.
Critical Analysis
- Therapeutic claims are narrower than compound claims but vital for market exclusivity.
- Enforceability depends on demonstrating clinical efficacy and non-obviousness, which the patent discloses in its specification.
Limitations & Challenges
| Issue |
Impact |
Notes |
| Chemical Diversity |
May allow design-arounds |
Cited substitutions are specific but could be circumvented with structural modifications outside the scope |
| Therapeutic Narrowness |
Limits exclusivity |
Use claims target certain diseases, but broader claims could enhance coverage |
| Prior Art |
Requires careful patentability analysis |
Existing patents on related compounds and methods challenge obviousness |
Key Takeaways
- U.S. Patent 8,367,102 offers a solid protective barrier around specific arylcyclohexylamine derivatives with applications in autoimmune and inflammatory disease treatment.
- Its claims blend chemical structure restrictions, synthesis methods, and therapeutic uses, balancing breadth and enforceability.
- The patent landscape features complex patent thickets, with numerous related patents covering synthesis, analogs, and formulations.
- Companies seeking to leverage this patent should consider licensing or design-around strategies, especially regarding the chemical substitution patterns and therapy claims.
- Continuous monitoring of subsequent filings and potential patent litigations remains vital, given the length of patent life and ongoing innovation in this space.
FAQs
1. Can I develop a compound similar to those in U.S. Patent 8,367,102 without infringing?
Yes. If the new compound differs significantly in chemical structure, especially outside the scope of the claims' defined substitutions, it may not infringe. However, legal advice is recommended for specific compounds.
2. How does this patent compare to other patents in the same therapeutic class?
It is relatively focused on the chemical space of trans-4-arylcyclohexylamines with specific use claims, providing targeted protection whereas some related patents may have broader chemical or use coverage.
3. What are the main challenges in assessing infringement of this patent?
The main challenges include determining whether a compound falls within the chemical scope of the claims and whether the use or synthesis methods used are covered by the patent’s claims.
4. Is the patent still enforceable, and what is its expiration?
Yes, the patent is enforceable until approximately March 2030, assuming no legal challenges or terminal disclaimers.
5. Are method-of-treatment claims strong in pharmaceutical patents?
They can be, but often require evidence of efficacy and novelty. Their strength depends on how specifically the claims define the therapeutic process and whether prior art discloses similar methods.
References
[1] U.S. Patent 8,367,102, "Arylcyclohexylamine derivatives and methods of synthesis and use," granted March 19, 2013.
[2] Patent landscape reports on autoimmune and inflammatory therapeutics [cited sources based on patent searches].
[3] Factual analysis based on patent claim structures and legal precedents in patent law.
More… ↓
⤷ Start Trial
|
